Basic Information
| LncRNA/CircRNA Name | circZFR |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular cancer |
| ICD-0-3 | NA |
| Methods | qRT-PCR, CCK-8 assay, Colony formation assay, Western blot, Luciferase reporter assay |
| Sample | HCC tissues, HCC cell lines (MHCC97H, Hep3B, Huh7 and Bel-7402), normal hepatocyte cell line (L-02) |
| Expression Pattern | up-regulated |
| Function Description | loss-of-function assay indicated that circZFR knockdown significantly suppressed cell proliferation and epithelial-mesenchymal transition (EMT) in HCC. Then bioinformatics tools predicted that cicrZFR enhanced the CTNNB1 expression via sponging miR-3619-5p. In summary, our findings indicated that circZFR may exert carcinogenic role in HCC through regulating miR-3619-5p/CTNNB1 axis and activating Wnt/?-catenin pathway. These findings may provide a novel perspective for the treatment of hepatocellular carcinoma. |
| Pubmed ID | 30468709 |
| Year | 2018 |
| Title | CircZFR promotes hepatocellular carcinoma progression through regulating miR-3619??p/CTNNB1 axis and activating Wnt/?-catenin pathway |
External Links
| Links for circZFR | GenBank HGNC NONCODE |
| Links for hepatocellular cancer | OMIM COSMIC |